Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
Giorgio V. Scagliotti, Thomas Brodowicz, Frances A. Shepherd et al. · Journal of Thoracic Oncology · 2010
Cited by 252 works. doi:10.1097/jto.0b013e3181f7c6d4
Authors
- Giorgio V. Scagliotti
- Thomas Brodowicz
- Frances A. Shepherd
- Christoph Carl Zielinski
- Johan Vansteenkiste
- Christian Manegold
- Lorinda Simms
- Frank V. Fossella
- Katherine P. Sugarman
- Chandra Prakash Belani
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer